By Shelly Kumar
Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that effective immediately its common shares have been approved for trading on OTCQX®, the highest tier of the OTC market, exclusively for US and international companies that undergo a rigorous financial and qualitative review. The Company’s common shares will
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
By Shelly Kumar
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.
“The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers
Oncolytics Biotech shared the results from a positive End-of-Phase 2 meeting with the FDA for REOLYSIN in combination with paclitaxel.
ImmunoPrecise announced it was awarded the first commercial humanizing antibody project from an undisclosed biotech company.
CorMedix announced its chief scientific officer Dr. Antony Pfaffle will present at an upcoming biotech conference.
Oncolytics Biotech announced the presentation of two posters on REOLYSIN at the European Society for Medical Oncology.
Moleculin Biotech entered into a collaborative agreement with the University of Bergen to test WP1122 in combination with Roche Pharma’s drug Avastin(R).
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.